Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Purchased by Sei Investments Co.

Sei Investments Co. increased its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 634.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,576 shares of the company’s stock after purchasing an additional 35,052 shares during the quarter. Sei Investments Co. owned 0.15% of Establishment Labs worth $1,844,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Concurrent Investment Advisors LLC acquired a new stake in Establishment Labs in the first quarter valued at $263,000. SG Americas Securities LLC acquired a new stake in Establishment Labs in the second quarter valued at $303,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Establishment Labs in the second quarter valued at $373,000. Bayesian Capital Management LP acquired a new stake in Establishment Labs in the first quarter valued at $631,000. Finally, Principal Financial Group Inc. acquired a new stake in Establishment Labs in the second quarter valued at $593,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Trading Up 8.2 %

Establishment Labs stock opened at $45.25 on Friday. The stock has a market cap of $1.25 billion, a PE ratio of -14.41 and a beta of 1.20. The stock has a 50-day moving average price of $42.62 and a 200 day moving average price of $47.10. Establishment Labs Holdings Inc. has a 52 week low of $16.96 and a 52 week high of $60.12. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The company had revenue of $44.12 million for the quarter, compared to analysts’ expectations of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The company’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.65) EPS. Equities research analysts predict that Establishment Labs Holdings Inc. will post -2.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 3,641 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $45.04, for a total value of $163,990.64. Following the sale, the chief executive officer now directly owns 210,735 shares of the company’s stock, valued at approximately $9,491,504.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.44% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Stephens reissued an “overweight” rating and issued a $68.00 target price on shares of Establishment Labs in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price target on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Finally, Citigroup raised their price target on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.60.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.